TickerSpark Feed

healthcare

Everything tagged "healthcare" across the TickerSpark archives.

Agilent Technologies, Inc. (A) gains on earnings beats

Agilent Technologies, Inc. (A) gains after reporting earnings beats, lifting shares 4.0% as investors react to stronger-than-expected quarterly results.

Aug 26, 2026·2 MIN

Healthcare Medical - Diagnostics & Research

Earnings FlashPAHC

Phibro Animal Health Corporation (PAHC) rises on earnings beats

Phibro Animal Health Corporation (PAHC) rises 6.2% after posting earnings beats, lifting shares as investors react to stronger-than-expected quarterly results.

Aug 26, 2026·2 MIN

Healthcare Drug Manufacturers - Specialty & Generic

Research ReportROIV

Roivant Sciences (ROIV): Cash-Rich Biotech With Launch Catalysts

Roivant Sciences is a cash-rich biotech platform with a near-term brepocitinib launch and several late-stage catalysts, but valuation already reflects meaningful execution risk. The stock is a Hold as investors wait for commercial proof and clinical readouts.

Aug 25, 2026·20 MIN

Healthcare Biotechnology Biotech

Research ReportALNY

Alnylam Pharmaceuticals (ALNY): AMVUTTRA Drives a Buy Case

Alnylam has crossed into profitable commercial-stage biotech, powered by AMVUTTRA and a fast-growing TTR franchise. Valuation is rich, but the company’s revenue growth, cash generation, and pipeline support a Buy rating.

Aug 24, 2026·23 MIN

Healthcare Biotechnology Biotech

Research ReportMRK

Merck & Co. (MRK): Pipeline Growth vs. Keytruda Risk

Merck is a high-quality pharma franchise with strong cash flow, but the stock is balancing new product growth against looming Keytruda exclusivity risk. The shares look fairly valued at current levels, supporting a Hold.

Aug 23, 2026·22 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportISRG

Intuitive Surgical (ISRG): Recurring Revenue Powers Growth

Intuitive Surgical posted 19% Q2 2026 revenue growth, driven by a larger da Vinci installed base and a recurring revenue mix that reached 85% of quarterly sales. The stock still earns only a Hold as a premium valuation limits upside despite strong operating momentum.

Aug 22, 2026·21 MIN

Healthcare Medical Instruments & Supplies Healthcare

Research ReportLLY

Eli Lilly (LLY): Growth Power Meets Rich Valuation

Eli Lilly delivered 48% Q2 revenue growth and raised full-year guidance, but the stock already prices in a lot of that momentum. Hold reflects strong execution, a deep pipeline, and a premium valuation that limits upside.

Aug 21, 2026·20 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportTEM

Tempus AI (TEM): Growth Is Real, Profitability Isn’t Yet

Tempus AI is scaling quickly in oncology diagnostics and data licensing, but losses, negative free cash flow, and leverage keep the stock in Hold territory.

Aug 20, 2026·19 MIN

Healthcare Health Information Services Healthcare

OpinionTEM

Tempus AI's 24% stealth rally is a bull signal, not a mystery

TEM’s 24.1% headline-free surge looks like investors repricing a real profitability inflection, not chasing an empty AI story. Q2 revenue growth, a guidance raise and a path to positive cash flow give the rally a fundamental anchor despite expensive valuation.

Aug 20, 2026·2 MIN

AI Healthcare Valuation

Research ReportBNTX

BioNTech (BNTX): Oncology Pipeline Drives the Turnaround

BioNTech is moving from fading COVID-19 vaccine revenue to a multi-product oncology pipeline, but near-term earnings remain weak. Its cash-rich balance sheet supports the transition, yet the stock still depends on late-stage clinical execution.

Aug 19, 2026·22 MIN

Healthcare Biotechnology Biotech

Research ReportAZN

AstraZeneca (AZN): Oncology Momentum Drives a Buy Case

AstraZeneca’s oncology and respiratory franchises are offsetting legacy erosion, supporting a Buy rating despite leverage and trial risk. The stock looks reasonably valued with multiple late-stage catalysts still ahead.

Aug 18, 2026·21 MIN

Healthcare Drug Manufacturers - General Biopharma

Research ReportVRTX

Vertex Pharmaceuticals (VRTX): CF Momentum and Pipeline Expansion

Vertex is executing well across cystic fibrosis, with ALYFTREK, CASGEVY, and JOURNAVX all contributing to growth while the renal pipeline and Crinetics deal broaden the story. The stock earns a Buy on durable cash generation and a fair value estimate of $560.